-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Diffuse glioma is a malignant brain tumor, including low-grade glioma (LGG) and glioblastoma.
The study included 66 patients with advanced glioma, ivosidenib was administered orally every day for a period of 28 days.
The results showed that ivosidenib was well tolerated and no dose-related toxicity was reported.
Among patients with non-enhanced glioma (n = 35), the objective response rate was 2.
The median progression-free survival in the non-enhanced and enhanced glioma cohorts were 13.
In summary, the results of this study show that in patients with mIDH1 advanced glioma, ivosidenib 500 mg once a day has good safety, prolongs the time of disease control, and reduces the growth rate of non-enhanced tumors.
Original source:
Ingo K Mellinghoff, et al.
ncbi.
Leave a message here